Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $2M | $9M | $23M | $36M | $34M | $22M | $10M | — | — | — |
| Enterprise Value | $8M | $8M | $21M | $32M | $36M | $35M | $26M | $10M | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.68 | 20.57 | 2.07 | 1.24 | 1.99 | 2.99 | 9.43 | 9.87 | — | — | — |
| P/B Ratio | — | — | — | — | 3.86 | 3.81 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 108.03 | 5.09 | 1.72 | 1.98 | 3.06 | 11.19 | 10.13 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.1% | 23.1% | 8.6% | 29.5% | 32.7% | 22.8% | 15.8% | 50.0% | 53.8% | 50.8% | 52.1% |
| Operating Margin | -19415.6% | -19415.6% | -386.2% | -81.1% | -118.3% | -257.0% | -767.9% | -46.2% | 5.1% | -17.6% | -4.9% |
| Net Profit Margin | -34537.0% | -34537.0% | -571.7% | -111.4% | -120.7% | -256.7% | -1246.7% | -504.6% | 5.2% | -16.5% | -4.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -1130.2% | -240.1% | -662.4% | — | — | — | — | -255.8% |
| ROA | -1354.9% | -1354.9% | -375.4% | -154.4% | -129.6% | -226.9% | -594.2% | -1231.1% | 21.0% | -49.5% | -16.4% |
| ROIC | — | — | — | -181.7% | -169.0% | -319.1% | -664.0% | -592.1% | 148.9% | -289.3% | -41.3% |
| ROCE | — | — | — | -408.3% | -192.4% | -424.1% | -983.1% | — | 2348.5% | -5139.1% | -118.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.47 | 0.57 | — | — | — | — | 2.69 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 0.62 | — | 18.51 |
| Net Debt / Equity | — | — | — | — | -0.01 | 0.10 | — | — | — | — | 1.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 0.56 | — | 7.80 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.57 | -4.57 | -2.22 | -2.69 | -85.05 | -65.27 | -8.89 | -533.73 | 12.94 | -32.06 | -9.46 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | 0.04 | 0.10 | 0.27 | 2.15 | 1.29 | 0.41 | 0.59 | 0.86 | 0.65 | 1.01 |
| Quick Ratio | 0.04 | 0.04 | 0.05 | 0.12 | 1.40 | 0.99 | 0.27 | 0.55 | 0.76 | 0.56 | 0.92 |
| Cash Ratio | 0.02 | 0.02 | 0.00 | 0.03 | 0.89 | 0.65 | 0.07 | 0.04 | 0.02 | 0.06 | 0.21 |
| Asset Turnover | — | 0.08 | 1.51 | 1.90 | 1.05 | 0.69 | 0.25 | 2.39 | 3.21 | 3.71 | 2.85 |
| Inventory Turnover | 1.67 | 1.67 | 4.25 | 5.90 | 3.27 | 4.54 | 2.43 | 16.65 | 14.52 | 17.47 | 19.22 |
| Days Sales Outstanding | — | 544.35 | 55.48 | 21.77 | 43.52 | 37.30 | 91.37 | 111.03 | 83.92 | 61.66 | 74.37 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $544599 | $334607 | $265310 | $233687 | $180627 | $38622 | $24611 | $23720 | $23494 | $23494 |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EDVA stock.
Endovia Health Sciences, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Endovia Health Sciences, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Endovia Health Sciences, Inc. has 23.1% gross margin and -19415.6% operating margin.
Key Metrics
Top Statement Risk
Imminent Going Concern Risk
Metrics are mathematically derived from official filings.
Distressed Valuation Amidst Revenue Collapse
According to recent market data, SBEV trades at a price-to-sales ratio of 5.74, a figure that appears fundamentally disconnected from the company's 98% revenue decline and suggests that market participants may be mispricing the firm as a viable operating entity rather than a distressed asset.
The current valuation multiples are largely non-meaningful due to the absence of positive earnings or EBITDA, rendering standard P/E and EV/EBITDA metrics inapplicable. Investors should monitor the P/B ratio of 0.33, which indicates that the market is pricing the company well below its book value, likely reflecting deep skepticism regarding the recoverability of remaining assets.
Structural Inability to Generate Margins
As reported in financial statements, SBEV's gross margin has fluctuated significantly, with recent periods showing negative values that highlight a fundamental inability to cover production costs, a stark contrast to the stable profitability profiles observed in the broader consumer defensive beverage sector.
The extreme operating margin of -19415.62% suggests that the company's fixed cost base is entirely disproportionate to its current revenue generation capacity. This level of margin erosion implies that the business model, in its current configuration, is incapable of achieving the scale necessary to reach even a break-even point.
Working Capital Management Remains Dysfunctional
Based on the company's reported figures, the cash conversion cycle has reached extreme levels, with recent data indicating a CCC of 1131 days, which suggests that the company is facing severe friction in its ability to convert inventory into cash or manage supplier payment terms effectively.
The erratic nature of the days sales outstanding and days inventory outstanding metrics points to a breakdown in operational efficiency. This lack of velocity in the supply chain likely exacerbates the company's liquidity constraints, as capital remains trapped in slow-moving or potentially obsolete inventory.
Critical Liquidity Shortfall Threatens Operations
As evidenced by the most recent quarterly filings, SBEV's current ratio has plummeted to 0.04, a level that indicates an acute inability to meet short-term financial obligations and suggests that the company is operating in a state of extreme financial fragility.
With cash reserves dwindling to nominal levels, the company appears to have virtually no buffer to absorb further operational shocks or to fund necessary marketing and distribution efforts. This liquidity position warrants significant concern, as it leaves the firm highly dependent on external financing that may be difficult to secure.
Misapplication of Revenue-Based Valuation Metrics
Based on an analysis of the company's business model, the most commonly misapplied metric is the price-to-sales ratio, which obscures the reality that SBEV's revenue has effectively evaporated and no longer serves as a reliable indicator of future cash flow generation or operational health.
Investors should instead focus on the cash burn rate and the remaining liquidity runway, as these metrics provide a more accurate assessment of the company's survival prospects. Relying on revenue multiples in a distressed context risks ignoring the fundamental reality that the company's core commercial operations have largely ceased to function.